ABSI Absci: תחזית צמיחת רווחים לשנה הבאה
Absci integrates generative AI and robotics for instantaneous digital antibody design, eliminating routine labor. This time-series projection of future earnings per share growth on the GURU.Markets chart reflects expectation dynamics, where the value 7.20 describes the current level. Absci is implementing innovative de novo drug design while simultaneously expanding its computing power and modernizing its high-tech laboratories.
ABSI (absci.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
The integration of the Absci (ABSI) AI platform into drug development in collaboration with Merck and AstraZeneca is accelerating the commercialization of antibodies. By analyzing analyst benchmarks for 12-month EPS growth, investors can track the trend of expected net income for the coming year. This metric mathematically captures changes in earnings forecasts, allowing a distinction between genuine fundamental stability and market noise. This indicator defines the security's status as a high-tech asset dependent on the pace of partnership implementation.
